Avalon GloboCare (Nasdaq: ALBT) Evolving To Potentially Become A Precision Diagnostics and Health Management Powerhouse

Avalon GloboCare (Nasdaq: ALBT) Is Evolving To Potentially Become A Precision Diagnostics and Health Management Powerhouse FDR Member, This is Michael Reece with "Financial Driven Research" delivering you your breakout alert for today's trading session, we are back on Avalon GloboCare (Nasdaq: ALBT) While there is a literal plethora of emerging biotech presenting investment opportunities, they certainly aren't a basket of equals. Some look good, others sound good, and others, well, they have the technology and assets to check both boxes. That's less common than you may think. While on an ambitious pathway to monetizing assets, hundreds of emerging biotech’s, even some of the ones we've covered, still need time, capital, and a favorable FDA opinion to commence their marketing ambitions. That's okay. Priced according to its position, many present extraordinary early investment opportunities. And those are the types of companies we like to feature- the ones that have great technology, are advancing a commercialization agenda, and have assets that differentiate themselves from an often crowded and competitive landscape. Having all of that and more is Avalon Globocare Corp. (NASDAQ: ALBT), a commercial-stage health management company that has made several strategic moves in 2024 intended to accelerate revenue growth and establish a more formidable footprint in the precision diagnostics and clinical laboratory services sectors. Pay attention…  Members... ALBT is doing more than targeting value from a potentially lucrative healthcare segment; they are doing so with a small trading float of just 4.89 million shares from a total outstanding count of about 11.1 million. Also attractive is that ALBT stock trades with ample liquidity, averaging 2.9 million shares exchanged daily. That capital structure should be appealing to both fast-lane and patient members, who, after due diligence, can feel comfortable with a quick gain or with the longer-term potential to capitalize on the accrual of gains expected from each milestone reached. Several could be in the crosshairs, resulting from ALBT's commitment to developing and delivering innovative, precision diagnostics and clinical laboratory services whose differences are competitive advantages. Helping turn ambitions into tangibles, ALBT's mission was strengthened after completing the acquisition of a 40% membership interest in Laboratory Services MSO, LLC (LSM) last year. This acquisition is more than a value-driver from an investor's perspective; it marked a significant step forward in Avalon's intent to establish a leading role in the innovation of diagnostic testing by leveraging value with LSM's robust portfolio of diagnostic services, which aligned perfectly with Avalon's vision. In other words, this deal is accretive and, more importantly, allows ALBT to benefit quickly and efficiently by integrating and offering a wide range of high-quality diagnostic tests, including general bloodwork, toxicology, and specialized genetic testing. The two are wasting no time capitalizing on the combined strengths. In July, Avalon GloboCare Corp. announced that it has launched a direct-to-consumer DNA test in the U.S. aimed at identifying genetic predispositions to opioid dependence. Value drivers are already in play… The screen, called the DNA4Addiction Test, analyzes 15 genetic markers related to opioid dependence, offering users insights into their potential risk levels (High, Moderate, or Reduced Risk). Keep in mind that this is not a diagnostic tool. That's what's cool about it. It's part of a shift to proactive health management, which is becoming a pivotal inclusion regarding health and prevention management. It's an innovation that's needed, considering that opioids are involved in over 75% of over 81,000 drug overdose fatalities in the U.S. during 2023. The test is available at www.dna4addiction.com and can be invaluable in empowering individuals to make informed decisions about their health and lifestyle. That product and contributions from LSM are not the only value drivers. Also in July, ALBT announced launching online U.S. sales for the KetoAir™ breathalyzer device and related accessories. The commercially available product that can be purchased at www.ketoair.us is another innovative product with significant revenue-generating potential. It targets the massively popular KETO generation and uses AI-enabled software and nano-sensor-based technology for ketogenic health management. It's a revolutionary addition to ketosis management that could earn accelerated adoption from those often using imperfect urine strips to determine levels of ketosis. You know, the ones where users try to convince themselves that their code color is darker than it is to justify the dietary restrictions. That's not the case with KetoAir.™ The KetoAir™ breathalyzer gives users real-time insights into their ketosis status, and the associated app offers personalized diet and exercise recommendations. As popularity and expected adoption increases for the product, ALBT is in an enviable position to exploit value by holding exclusive distribution rights from Qi Diagnostics Ltd. for the KetoAir™ in North America, South America, the E.U., and the U.K. This "blow to know" product launched with an introductory price of $199 after a 20% discount code. Do the math- if it gains the sales traction as expected, it can indeed be transformative to revenue growth. KetoAir™ attracts interest… And it very well may. In June, Avalon updated interested attendees about its KetoAir™ breathalyzer at the Hack Your Health by KetoCon 2024 Conference in Austin, Texas. According to ALBT, the product attracted interest from various stakeholders, including healthcare providers, keto coaches, and retailers. Furthermore, the company highlighted the launch of the Zero to Keto program for health and keto coaches, which is expected to generate a running start in booking potentially significant retail sales orders. Keep in mind that this isn't a gimmick toy. The KetoAir™ breathalyzer is registered with the FDA as a product able to assist with ketogenic health management by offering a non-invasive and sanitary way to monitor their ketosis state and body fat-burning rate. Remember, too. Many following Keto restrictions are doing so for reasons other than losing a few pounds. While it's a target market, Avalon is also positioning to target the diabetes reversal and obesity markets, leveraging the ketogenic diet's effectiveness in these areas. Thus, if insurance reimbursement comes into play, revenue growth could turn from expected impressive to exponential. That potential wild card may indeed become a reality, especially after ALBT engaged ChtrBx, a marketing and branding company tasked with developing a global marketing launch plan for the KetoAir™ breathalyzer, which will include traditional advertising, P.R., retail support, celebrity endorsements, and digital programming. So, keep in mind if ALBT publishes impressive sales numbers. What's happening now is considered a "soft launch." The full-scale launch will commence in 2025 and attack sales channels developed since late 2023. A value proposition exposed… So, as an investor, is trading ahead of an expected series of value-creating announcements a wise consideration? A lot of due diligence, grinding the numbers, and evaluating potential support an emphatic YES answer. In fact, whatever you measure as an investor to support the bullish thesis, ALBT has a solid answer. It has excellent and distinguishing diagnostics through its 40% interest in LSM, has game-changing products targeting the massive Keto market, and holds exclusive licensing to not only get a competitive leg up in the Keto market but is also positioned uniquely to offer millions of people with a tool to pro-actively manage lifestyle to avoid opioid addiction. For roughly $0.27 a share yesterday, ALBT is a stock presenting a significant value proposition ripe for the taking. Low float, low O/S, great products, exclusive licensing, and a mission to provide the products and services people need to live healthier, happier, and more productive lives. Other than what's best described as a significant value disconnect between ALBT assets, potential, and share price, ALBT may be as good as it gets when it comes to companies wanting, willing, and able to inspire positive change. For those reasons alone we like this company. Factor in the compelling value proposition, while the gurus say you should never- we love it. To Your Trading Success, Michael Reece Editor, Financial Driven Research Source Appendix: [~:text=The%20new%20data%20show%20overdose,psychostimulants%20(like%20methamphetamine)%20increased.]( [( [( [( [( [( [( [( [( [( [( © 2024 Financial Driven Research, All Rights Reserved. Financial Driven Research (“FDR” or “Company”) is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inves∙tment for any specific individual. FDR full disclosure is to be read and fully understood before using FDR website or joining FDR email or sms list. By viewing FDR website and/or reading FDR email or sms list you are agreeing to FDR full disclosure This publication may contain information regarding inves∙tment ideas and third-party ratings regarding specific securities. We hold n∙o inves∙tment licenses and are thus neither licensed nor qualified to provide inves∙tment adv∙ice. FDR nor its principals are not FINRA-registered broker-dealers or inves∙tment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from FDR to buy or sell any security. Always be extremely careful and consult a licensed inves∙tment professional before making any inves∙tment decision as inves∙ting in securities carries a high degree of risk; you may likely lose some or all of the inves∙tment. This communication is a sponsored advertisement. FDR and/or its subsidiaries and/or affiliates have been compensated up to $20,000 USD to disseminate this communication. Please note we do not hold positions in stocks we profile. We do not trade in any of our sponsored advertisements, or non-sponsored profiles. We do not accept stock as a form of payment for our sponsored advertisements. Please review the full disc∙laimer at [Disc]( and Disclosure Policy]( for important information regarding this sponsored advertisement. © 2023 FDR. All rights reserved., 1014 W 36th St, Baltimore, MD 21211, United States You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](